Avicanna to Present at the Life Science Investor Forum June 20th, 2024
Avicanna to Present at the Life Science Investor Forum June 20th, 2024
Investors, advisors and analysts, will have the opportunity to attend in-person or participate online at VirtualInvestorConferences.com
投資者、顧問和分析師,將有機會親自參加或在VirtualInvestorConferences.com上線上參加。
TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce Aras Azadian CEO of Avicanna will be delivering a presentation live at the Life Science Investor Forum with Virtual Investor Conference hosted by VirtualInvestorConferences.com on June 20, 2024.
2024年6月18日,多倫多,加拿大通訊社——Avicanna Inc.(以下簡稱“Avicanna”或“公司”)(TSX: AVCN)(OTCQX: AVCNF)(FSE: 0NN)是一家生物製藥公司,專注於植物源性大麻二酚類產品的開發、製造和商業化,很高興宣佈Aras Azadian先生,Avicanna的首席執行官,將在VirtualInvestorConferences.com舉辦的Life Science Investor Forum主持的Virtual Investor Conference上直播演講於2024年6月20日。
Aras Azadian will provide a corporate update on Avicanna and will then also be joined by Brad Sorensen, senior equity research analyst with Zacks Small-Cap research for a fire-side chat. This will be a live, interactive online event where attendees have the opportunity to ask the Company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
Aras Azadian先生將提供關於Avicanna的公司更新,然後還將與Brad Sorensen先生一起進行現場交流。 Brad Sorensen先生是Zacks Small-Cap研究的高級股票研究分析師。這將是一次實時的互動在線活動,與會者有機會實時向公司提出問題。如果與會者不能在會議當天現場參加活動,則檔案錄像也將在活動後提供。
DATE: June 20th 2024
TIME: 12:00pm EST
LINK:
日期:6月20日th 2024
時間:加東時間下午12:00
鏈接:
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at .
建議在線投資者提前註冊並運行在線系統檢查,以加快參與和接收活動更新。了解更多有關此活動的信息。
Recent Company Highlights
公司近期亮點
- First adjusted EBITDA positive quarter in Avicanna's history
- 2023-year end results and Avicanna achieving 314% year-over-year revenue increase
- First indication-specific drug approval of Avicanna's Trunerox product
- Avicanna歷史上首個調整後EBITDA爲正的季度
- 2023年末的結果以及Avicanna實現314%的年度營業收入增長
- Avicanna的Trunerox的首個適應症特異性藥物批准每$1,000金額的面值產品。
About Avicanna Inc.
關於Avicanna Inc。
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars.
Avicanna是一家專注於爲全球醫療和製藥市場推進和商業化基於大麻二酚類產品和製劑的國際商業化階段的生物製藥公司。 Avicanna擁有一個成熟的科學平台,包括研發和臨床開發,導致商業化超過30種專有的、基於證據的成品和支持四個商業化階段的業務支柱。
Medical Cannabis formulary (RHO Phyto): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient, and medical community education. RHO Phyto is an established leading medical brand in Canada currently available nationwide to patients across several medical channels and continues to expand into new international markets.
醫用大麻製劑(RHO Phyto):該製劑提供多種專有產品,包括口服、舌下、局部和經皮遞送,具有不同的大麻二酚比例,並得到持續的患者、醫療界的支持和教育。 RHO Phyto是加拿大的一個成熟的領先醫療品牌,目前在加拿大全國範圍內向幾個醫學渠道的患者提供服務,並不斷擴展至新的國際市場。
Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients' needs and enhance the patient journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.
醫用大麻護理平台(MyMedi.ca):MyMedi.ca是一個醫用大麻護理平台,旨在更好地服務醫用大麻患者的需求並增強患者的旅程。 MyMedi.ca由Northern Green Canada Inc.運營,並提供多種產品和雙語藥劑師主導的患者支持計劃。 MyMedi.ca還爲不同的患者群體提供專業服務,例如退伍軍人,並與公共和私人付款方進行合作以進行裁決和報銷。 MyMedi.ca向醫療界提供教育資源,以促進將醫用大麻納入醫療保健方案中。
Pharmaceutical products (Trunerox) and pipeline: Leveraging Avicanna's scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific pharmaceutical products that are in various stages of clinical development. These cannabinoid-based drug candidates aim to address unmet medical needs in dermatology, chronic pain, and various neurological disorders. Avicanna's first indication-specific pharmaceutical drug, Trunerox, was approved Q1 2024 by the Health Authority of Colombia INVIMA as an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome in Colombia. Trunerox has not been approved as a drug in Canada by Health Canada.
藥品(Trunerox)和管線:利用Avicanna的科學平台、垂直整合和現實世界的證據,Avicanna開發了一系列專有的、適應症特異性的藥物產品,這些大麻二酚類藥物候選品處於不同的臨床開發階段。這些基於大麻二酚的藥物候選品旨在解決皮膚病、慢性疼痛和各種神經系統疾病的未滿足醫療需求。Avicanna的首個適應症特異性製藥品Trunerox已於2024年第一季度獲得哥倫比亞衛生局INVIMA批准,作爲哥倫比亞Lennox-Gastaut綜合症和Dravet綜合症相關症狀的輔助治療藥物。在加拿大,Trunerox並未獲得健康加拿大的批准。活性藥物成分(Aureus Santa Marta):活性藥物成分由公司的多數持股子公司Santa Marta Golden Hemp SAS供應,該子公司是一個商業化階段的企業,致力於爲公司的國際合作夥伴提供各種高質量的CBD、THC和CBG以供食品、化妝品、醫療和製藥產品的開發和生產使用。該業務部門還是公司供應鏈的一部分,併爲其消費零售、醫用大麻和製藥產品在全球範圍內提供可靠的輸入產品。
Active pharmaceutical ingredients (Aureus Santa Marta): Active pharmaceutical ingredients are supplied by the Company's majority owned subsidiary Santa Marta Golden Hemp SAS which is a commercial-stage business dedicated to providing a various forms high-quality CBD, THC and CBG to the Company's international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. The business unit also forms part of the Company's supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally.
Avicanna Inc.消息來源。
SOURCE Avicanna Inc.
有關Avicanna的更多信息,請訪問
Stay Connected
保持聯絡。
For more information about Avicanna, visit our website, contact Ivana Maric by email at info@avicanna.com or follow us on social media on LinkedIn, Twitter, Facebook, or Instagram.
我們的網站,通過電子郵件聯繫Ivana Maric,地址爲info@avicanna.com,或在社交媒體上關注我們,請通過info@avicanna.com電子郵件聯繫Ivana Maric,或在社交媒體上關注我們LinkedIn, 推特, Facebook,或Instagram.
The Company posts updates through videos from the Company YouTube channel.
公司通過公司渠道發佈視頻更新。YouTube。
Cautionary Note Regarding Forward-Looking Information and Statements
關於前瞻性信息和聲明的注意事項本新聞發佈包含適用證券法的“前瞻性信息”。本新聞發佈中所包含的前瞻性信息可以通過諸如“可能”、“會”、“可能”、“將”、“可能”、“預期”、“預計”、“相信”、“打算”、“計劃”、“預測”、“項目”、“估計”、“前景”等類似表達方式來識別。儘管公司認爲此類前瞻性信息所基於的期望和假設是合理的,但不應對前瞻性信息產生過度依賴,因爲公司無法保證其證明是正確的。實際結果和發展可能與這些聲明所考慮的有所不同。前瞻性信息受各種風險和不確定性的影響,可能會導致實際事件或結果與前瞻性信息中所預示的有所不同。此類風險和不確定性包括但不限於當前和未來市場條件,包括公司普通股的市場價格,以及公司於2024年4月1日提交給加拿大證券監管機構的年度信息表中列出的風險因素,該信息表可在公司在SEDA上的簡介下獲得。本新聞發佈中的陳述是在發佈日期作出的。公司否認任何意圖或義務更新任何前瞻性信息,除非適用證券法有要求外,否則不更新。
This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified using words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company's annual information form dated April 1, 2024 filed with the Canadian securities regulators and available under the Company's profile on SEDAR at . The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
本新聞稿包含適用證券法律的“前瞻性信息”。本新聞稿中包含的前瞻性信息可以通過使用“可能”、“會”、“可以”、“將會”、“有可能”、“期望”、“預期”、“相信”、“打算”、“計劃”、“預測”、“項目”、“估計”、“前景”和其他類似的表述來識別。雖然公司相信對此類前瞻性信息所依據的期望和假設是合理的,但不應過分依賴前瞻性信息,因爲公司不能保證其證明是正確的。實際結果和發展可能與這些聲明所考慮的情況有所不同。前瞻性信息面臨各種風險和不確定性,可能導致實際事件或結果與前瞻性信息中所預示的結果有所不同。此類風險包括但不限於當前和未來的市場條件,包括公司的普通股票市場價格,以及列於公司在 SEDAR 上的檔案下,於2024年4月1日的公司年度信息表中列出的風險因素。本新聞稿中的聲明是以此發佈日期爲基準。公司否認任何意圖或義務更新任何前瞻性信息,除非適用證券法律另有規定。